06 Mar 2020
- 20 February 2020: Phase II clinical trial for Brain metastases in non-small cell lung cancer (NSCLC) approved by the Taiwan Food and Drug Administration (TFDA)
- 27 February 2020: Komipharm files for emergency clinical trial of its investigative drug to treat coronavirus pneumonia, which is poised to become the first such study by a Korean company.
- 14 May 2020: Phase II clinical trial for Brain metastases in non-small cell lung cancer (NSCLC) approved by the Korean Ministry of Food and Drug Safety (MFDS).